Administration of interleukin 2 (IL-2
Introduction
Administration of intermittent cycles of interleukin 2 (IL-2) to patients infected with HIV-1 leads to substantial and sustained CD4 ϩ T-cell expansions. 1, 2 The initial induction regimen consists of 5-day cycles that are administered every 8 weeks for 3 to 6 cycles. The majority of treated patients then require only infrequent cycling for maintenance of these CD4 expansions. 3, 4 Studies with the use of ex vivo and in vivo labeling techniques have shown that significant proliferation of both CD4 ϩ and CD8 ϩ T cells occurs during IL-2 administration. Ultimately, selective expansion of only the CD4 ϩ T-cell pool is observed. 5, 6 It has also been reported that intermittent IL-2 leads to a preferential long-term increase of CD4 ϩ T cells expressing CD25, the ␣ chain of the IL-2 receptor. 3, 4 These observations have led to the hypothesis that IL-2 may be preferentially sustaining CD4 ϩ T-cell expansions via continued proliferation, a mechanism that contrasts with the mechanism described for antiretroviral therapy (ART). It is currently well established that HIV infection leads to a state of heightened immune activation and increased T-cell turnover. [7] [8] [9] In studies with in vivo labeling techniques, the degree of T-cell turnover was abnormally high compared to HIV-seronegative controls and correlated with plasma viremia levels, 10, 11 with highly active antiretroviral therapy (HAART) administration leading to viral suppression and a lowering of T-cell turnover, although not always to normal levels. In the current study the long-term effects of intermittent IL-2 therapy to T-cell turnover were tested by studying the proliferation of CD4 ϩ T cells of patients treated with IL-2 in comparison with patients treated with ART alone.
Patients, materials, and methods

Patients
Cohort 1. A total of 82 consecutive patients infected with HIV-1 who agreed to participate and signed informed consent were included in this study between December 1997 and June 1998. All participants were followed at the National Institute of Allergy and Infectious Diseases/ Clinical Center (NIAID/CC) clinic participating in Institutional Review Board (IRB)-approved protocols. The cohort included 40 patients (control group) who were not receiving IL-2 and were either receiving ART (35 patients) or were ART naive (5 patients), and 42 patients treated with intermittent cycles of subcutaneous IL-2 at doses of 4.5 to 7.5 million IU (MIU) 2 times a day for 5 days (IL-2 group) in combination with ART. All patients on therapy had received 3 months or longer of HAART and the majority of patients in both groups were receiving a protease inhibitorbased regimen. The characteristics of the participants (at the time of study) are shown in Table 1 . Cohort 2. Cryopreserved peripheral blood mononuclear cells (PBMCs) from 53 HIV-1-infected patients participating in a randomized, controlled, phase 2, IRB-approved protocol at the National Institutes of Health Clinical Center (NIH-CC) were used. The study design and the results of the clinical trial have been published previously. 1 Briefly, the study compared the CD4 ϩ T-cell counts in 2 groups of participants who had more than 200 CD4 ϩ T cells/L at baseline: a control group receiving nucleoside analogues alone and an IL-2 group receiving nucleoside analogues with intermittent cycles of IL-2. At baseline (month 0), there were no significant differences between the 2 groups and viral loads did not change significantly during the study in either group ( Table 2 ). The IL-2 group participants received 5-day continuous intravenous infusions of IL-2 at 18 MIU per day every 8 weeks for a total of 3 to 6 cycles. The end of study time point (month 12 or 14) was 2 to 6 months after the last administered IL-2 cycle. Twenty-nine of 31 patients from the IL-2 group and 24 of 29 from the control group were studied. Patient selection was based on availability of stored cryopreserved viable PBMCs at month 0 and month 12 or 14. One patient from the control group was excluded from the analysis because he had received IL-2 during the study. Baseline (month 0) and end of study (month 12) characteristics of cohort 2 are shown in Table 2 .
Flow cytometry
Ex vivo bromodeoxyuridine (BrdU) staining was performed as previously described. 8 Immunophenotypic analysis of cryopreserved PBMCs was performed using 4-color immunofluorescence as previously described 9 using the following monoclonal antibodies: CD4-peridinin chlorophyll protein (PerCP; clone SK7), CD8-PerCP (clone SK1), CD45RO-phycoerythrin (PE) or allophycocyanin (APC; clone UCHL-1), and CD27-fluroescein isothiocyanate (FITC; clone M-T271), all from BD/PharMingen Immunocytometry (San Jose, CA). Intracellular staining for the nuclear antigen Ki67 was performed using Ki67-PE (clone B56) and mouse IgG1-PE (clone MOPC-21) from BD/PharMingen. T-cell proliferation was defined as the percent of cells expressing Ki67. We have previously shown that there is a good correlation between Ki67 staining and in vivo and ex vivo BrdU staining. 11 Additionally, a strong correlation between Ki67 expression and surface staining with HLA-DR and CD38 in CD4 ϩ and CD8 ϩ T cells of HIV-infected patients has been described, so that intracellular Ki67 staining is also a good marker of immune activation. 12 To study naive and memory phenotypes, cells were stained with surface CD3, CD4 or CD8, CD45RO, and CD27 antibodies, markers that are known to remain stable with cryopreservation. Naïve cells were defined as CD45RO Ϫ CD27 ϩ . Memory cells were either defined as CD45RO ϩ CD27 ϩ (recall or central memory) or CD45RO ϩ CD27 Ϫ (effector memory). In the CD8 subset, a third population of memory cells was defined as CD45RO Ϫ 27 Ϫ (CD45RO Ϫ memory). Samples were collected on a fluorescence-activated cell sorting (FACS) Calibur (BD Immunocytometry) using CellQuest software. Approximately 1.5 to 2 ϫ 10 5 total events with a minimum of 5000 events in the CD4 ϩ or CD8 ϩ gate were collected per sample. Flow cytometry data were analyzed using FlowJo software (Tree Star, San Carlos, CA).
Statistical methods
Medians and distributions of the data for the 2 treatment groups were compared by the Wilcoxon 2-sample method. The median changes from baseline to month 12 were tested for significance by the Wilcoxon signed rank test. IL-2 and control group Pearson correlations were tested for equality by the Fisher z transformation for comparison of 2 independent correlations. Association between other variables was determined by the Spearman rank correlation. Linear regression and analysis of covariance were also used to quantify the relationship between variables. Adjustment of P values for multiple testing was done by the Bonferroni method.
Results
Patients with HIV treated with IL-2 have a lower basal proliferation rate of CD4 ؉ T cells compared to patients who are not receiving IL-2 despite similar HIV viral loads A cross-sectional analysis was performed of 82 patients treated with either combination ART without (40, control group) or with intermittent IL-2 (42, IL-2 group) at a single time point. The IL-2 group patients had a significantly higher CD4 ϩ T-cell count and a longer time since HIV diagnosis compared to the control group (Table 1) . Proliferation of CD4 ϩ T cells as measured by ex vivo BrdU incorporation was lower in the IL-2 group compared to the control group (P Ͻ .01; Table 1 ). An association of CD4 ϩ T-cell proliferation with viral load was noted in the control group (r ϭ 0.68, P Ͻ .001) as well as the IL-2 group (r ϭ 0.57, P Ͻ .001) as shown in Figure 1 . By analysis of covariance, the slopes of the regression lines for the IL-2 and control groups were not different (P ϭ .33) and therefore the regression lines were parallel differing by a constant amount over the tested viral load range; by this same method the intercept for the IL-2 group was determined to be statistically lower (P Ͻ .001) indicating that CD4 ϩ T-cell proliferation was lower in the IL-2 group compared to the control group by a constant amount over the entire range of viral load. When the CD4 ϩ T-cell count was statistically controlled for, by adding it to the regression model, the intercept or difference in the parallel regression lines was no longer significant (P ϭ .15) indicating that the direct effect of viral load on CD4 ϩ T-cell turnover was similar in the IL-2 group compared to the control group. There was no correlation between the years since diagnosis of infection and the CD4 ϩ or CD8 ϩ T-cell proliferation in either group (P Ͼ .3). An inverse correlation was noted between years of infection and the CD4 ϩ T-cell count in the control group only (r ϭ Ϫ0.41, P ϭ .02). For personal use only. on September 13, 2017. by guest www.bloodjournal.org From
IL-2 administration leads to increases in naive and recall memory CD4 ؉ T cells but not effector cells
To better characterize these observations, and to better define the subpopulations of cells that are expanded during IL-2 therapy, a longitudinal analysis was performed of patients participating in a randomized controlled trial of IL-2.
It is known that IL-2 administration leads to a preferential increase of naive CD4 ϩ T cells, although increases in memory cells are also seen. 2, 4 In this study, a statistically significant increase was seen in the naive and recall memory CD4 ϩ T cells of the IL-2 group at month 12 compared to month 0, and also compared to the control group at month 12 (Figure 2A-B ; P Ͻ .001 for all comparisons). No changes from baseline were observed in the effector memory pool. The median change of the percent of effector memory CD4 ϩ T cells was significantly different between the 2 groups with a decrease of 8.70% in the IL-2 group compared to a decrease of 0.10% in the control group (P ϭ .002).
In the CD8 ϩ T-cell subset, no statistically significant changes from month 0 were observed in the numbers of CD8 ϩ T-cell subsets in either group (Figure 2C-D) . The median change in the percent of recall memory CD8 ϩ T cells (ϩ2.20% in the IL-2 group versus Ϫ3.80% in the control group) and the median change of the effector memory CD8 ϩ T cells (Ϫ1.90% in the IL-2 group versus ϩ2.60% in the control group) were also significantly different between the 2 groups (P ϭ .002). This observation is in agreement with recent reports showing decreases of CD8 ϩ /CD38 ϩ T cells as well as rises of naive CD8 ϩ T cells after IL-2 treatment. 4 
IL-2 administration leads to decreased Ki67 expression in CD4 ؉ T cells
No significant differences in intracellular Ki67 expression in CD4 ϩ and CD8 ϩ T cells were seen at study entry (month 0) between the 2 groups. However, a statistically significant decrease in Ki67 expression in CD4 ϩ T cells was noted at month 12 in the IL-2 group (Figure 3 , P Ͻ .001), whereas no significant changes were observed in the controls. Although an overall drop was also detected in the Ki67 expression of the CD8 ϩ T cells in the IL-2 group, this did not reach statistical significance in the paired analysis possibly due to considerable variability among patients. However, the percent CD8 ϩ T cells expressing Ki67 at month 12 was significantly lower in the IL-2 compared to the control group (P Ͻ .01). In examining naive and memory subsets of T cells, statistically significant decreases in Ki67 expression were seen in naive and recall memory subsets of CD4 ϩ T cells (P ϭ .004 and P Ͻ .001, respectively) but not in the effector memory subset (Figure 4) . A significant decrease was also noted in the effector memory CD8 subset (P ϭ .05). No significant changes occurred in any of the subsets in the control group (data not shown).
T-cell activation was also measured in a subset of patients (18 from the IL-2 group and 12 from the controls) with HLA-DR and CD38 coexpression. Surface coexpression of HLA-DR and CD38 on T cells correlates strongly with intracellular Ki67 expression in both ART naive and ART-treated HIV-infected patients. 12 A statistically significant change at month 12 compared to month 0 In IL-2 recipients, significant increases in the naive and recall memory CD4 subsets (P Ͻ .001) were observed compared to month 0 values (paired analysis) and when they were compared to controls at month 12. No statistically significant changes were noted in the control group at month 12 compared to month 0, except for a significant decrease in recall memory CD4 ϩ T cells (P ϭ .01). were noted in the naive (P ϭ .004) and recall memory (P Ͻ .001) CD4 ϩ T-cell subsets. Trends were noted in the effector CD4 ϩ (P ϭ .06) and CD8 ϩ T cell pools (P ϭ .05).
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BLOOD, 1 AUGUST 2004 ⅐ VOLUME 104, NUMBER 3 For personal use only. on September 13, 2017. by guest www.bloodjournal.org From was noted in the percent of CD4 ϩ T cells coexpressing HLA-DR and CD38 in the IL-2 group compared to controls (Ϫ5.5 versus ϩ1.90, P Ͻ .01). The median change of the percent of CD8 ϩ T cells coexpressing HLA-DR and CD38 was also significantly different between groups (Ϫ2.70 in the IL-2 group versus ϩ4.65 in the control group, P ϭ .003, data not shown).
Changes in CD4 ؉ T cell basal proliferation were independent of viral load changes in patients treated with IL-2
The relationship between viral load and proliferation was studied in the 2 groups from the randomized cohort. Consistent with previous reports, an association between CD4 ϩ and CD8 ϩ T-cell proliferation and viral load was found at study entry in both groups (data not shown). This was preserved at the end of study only in the control group and changes of viral load in the control group correlated with changes in T-cell proliferation ( Figure 5 , r ϭ 0.48, P ϭ .04). In contrast, viral load changes in the IL-2 group were not associated with changes in the proliferation of CD4 ϩ T cells ( Figure 5 , r ϭ 0.11, P Ͼ .5). There was a significant correlation between the CD4 ϩ and CD8 ϩ T-cell proliferation in both groups at both month 0 and month 12 time points (P Ͻ .01, data not shown).
The expansion of CD4 ؉ /CD25 ؉ T cells after IL-2 administration was strongly associated with decreases in turnover of this subset
Several studies have clearly shown that IL-2 leads to a significant increase of CD4 ϩ T cells expressing CD25. 1, 13, 14 The same observation was made in this study. In the IL-2 group the median percent of CD4 ϩ T cells expressing CD25 increased from 19.6% to 53% and the CD4 ϩ /CD25 ϩ T-cell count increased from 89 cells/L to 360 cells/L (P Ͻ .001). The CD4 ϩ /CD25 Ϫ count did not change significantly in the IL-2 group (from 334 cells/L to 308 cells/L, P ϭ .7). No significant changes were seen in the control group in either subset (data not shown). CD25 is considered a marker of activation and the expansion of CD25-expressing CD4 ϩ T cells shown earlier was paradoxical given the observed decreases in Ki67 expression in the CD4 ϩ T-cell pool. To better understand this observation we studied Ki67 expression in CD4 ϩ /CD25 ϩ and CD4 ϩ /CD25 Ϫ cells at month 0 and month 12 ( Figure 6A ). In the IL-2 group the median Ki67 expression in CD4 ϩ /CD25 ϩ cells decreased significantly from 8% to 3% ( Figure 6B , P Ͻ .001). No significant change in Ki67 expression was observed in the CD4 ϩ / CD25 Ϫ cells ( Figure 6C ). No changes were seen in either subset in the control group. The decrease in expression of Ki67 strongly correlated with the expansion of this subset ( Figure 6B ). In agreement with our previous report, 3 the CD4 ϩ /CD25 ϩ cells in the IL-2 group at month 12 were predominantly of naive or recall memory phenotype (data not shown).
Discussion
This study has demonstrated that contrary to expectations, IL-2 administration to patients infected with HIV-1 leads to long-term decreases in CD4 ϩ T-cell proliferation. These decreases occurred in the naive, recall memory and CD25 ϩ CD4 subsets, were strongly correlated with the observed cell increases in these pools of cells, and were independent of changes in viral load. These data suggest that decreases in proliferation and immune activation are critical in sustaining the long-lived CD4 ϩ T-cell expansions that are seen in the setting of IL-2 administration.
Immune activation has been implicated as an independent factor affecting HIV disease progression. 15, 16 It has been hypothesized that persistent immune activation supports increased T-cell turnover leading to increased apoptosis and immunologic senescence as well as preferential loss of naive cells with accumulation of cells with effector, terminally differentiated phenotype. [16] [17] [18] Similar immunophenotypic changes have also been described in HIV seronegative persons with persistent immune activation due to other chronic infections. 19, 20 Several recent studies support the hypothesis that immune activation is a primary immunopathogenic mechanism underlying the loss of CD4 ϩ T cells in HIV infection. In an animal model, Silvestri and colleagues 21 described how sooty mangabeys that remain healthy with normal life spans and normal CD4 ϩ T-cell counts after simian immunodeficiency virus (SIV) infection have only minimal evidence of immune activation (slight increases in percent of CD4 ϩ T cells expressing Ki67) despite high levels of SIV viremia. Sousa et al 22 reported a cross-sectional analysis of patients infected with HIV-1 and HIV-2 and showed that at similar degrees of CD4 ϩ T-cell lymphopenia, HIV-2-infected patients had equally elevated CD4 ϩ T-cell turnover (measured by Ki67) and loss of naive T cells compared to patients infected with HIV-1 despite significantly lower levels of viremia. Interestingly, higher levels of immune activation even before HIV seroconversion have also been reported to correlate with faster AIDS progression after HIV infection in the Amsterdam cohort. 23 Persistently high turnover after combination ART initiation despite virologic success (viral load less than the limit of detection) has been associated with incomplete CD4 ϩ T-cell recovery. 12 Similarly, patients with suboptimal virologic control but high CD4 ϩ T-cell counts were found to have lower levels of immune activation compared to patients with similar viral loads but low CD4 ϩ T-cell counts. 24 Taken together, these data highlight the important role of immune activation in CD4 ϩ T-cell lymphopenia.
Based on these observations, therapies targeting immune activation such as corticosteroids, cyclosporine, or mycophenolate mofetil have been attempted in HIV infection [25] [26] [27] and in some instances have led to at least temporary CD4 ϩ T-cell increases. Although some of these efforts have been tempered due to significant toxicity 28 and concerns over viral load increases 26 or additional immunosuppression in patients with preexistent defective cellular immunity, this remains an area of active investigation.
This study clearly demonstrated that IL-2 lowered immune activation and CD4 ϩ T-cell proliferation and this effect was tightly connected to CD4 ϩ T-cell increases. This "normalization" of T-cell turnover, even in the presence of detectable viremia, brought about by direct manipulation of the immune system offers a new perspective on the role of IL-2 in the treatment of patients with HIV infection. This observation helps explain the lack of effect of IL-2 on viral load 29, 30 and the fact that CD4 ϩ T-cell increases have been observed with IL-2 even in the absence of ART. 31 Interestingly, despite significant acute immunostimulatory effects during the 5-day period of IL-2 administration 32 that were associated with transient viral bursts in the pre-HAART era, 33 IL-2 immunotherapy in HIV infection actually appears to act by decreasing immune activation and T-cell proliferation.
Our results from the cross-sectional study of patients treated with HAART receiving subcutaneous IL-2 supported the findings of the longitudinal study of patients receiving nucleoside analogues with intravenous IL-2. In the HAART-treated cohort, a lower CD4 ϩ T-cell proliferation was observed in patients treated with IL-2 compared to controls in a wide (3 log) range of viral load. Interestingly, this difference seemed to depend on the higher CD4 ϩ T-cell counts of the IL-2 recipients, and thus correlated with the desired biologic effect of intermittent IL-2 immunotherapy. Although an alternative interpretation could be that different infection times in the 2 groups led to these findings, the IL-2 group had a significantly longer time since diagnosis. This is presumably a close surrogate for time of infection. Additionally, the longitudinal randomized study confirmed these findings in a group of patients with suboptimal virologic control, where the added effect of viral load on T-cell proliferation could also be studied. In a randomized study testing the use of corticosteroids to improve the tolerance of IL-2 cycles, in patients receiving HAART, it was also found that the blunted CD4 ϩ T-cell expansions in the patients treated with steroids and IL-2 were associated with smaller Ki67 decreases in the CD4 ϩ T cell pool compared to the group that received IL-2 alone. 34 The fact that IL-2 leads to rises of specific subsets of CD4 ϩ T cells, naive and recall memory, without affecting the effector pool is most relevant for its potential clinical applications given the recently described dichotomy of functional characteristics of memory T cells. 35, 36 Our results suggest that although no beneficial effect toward active infections should be anticipated, one may expect improvement of host defenses against recall or neoantigens and that the timing of IL-2 with respect to immunizations should be carefully designed. Considering the fact that immunologic challenges with remote recall or neoantigens are infrequent in adults, the clinical efficacy of this approach will take time to establish. Phase 3 clinical trials addressing this question 37 are ongoing with results anticipated in 4 to 5 years.
In summary, intermittent IL-2 administration to HIV-infected patients decreased activation and proliferation of CD4 ϩ T cells. These decreases were observed in the naive, recall memory, and CD25 ϩ CD4 ϩ T-cell subsets, were independent of viral load changes, and correlated strongly with the degree of CD4 ϩ T-cell expansions. These data suggest that intermittent IL-2 treatment in HIV infection could be viewed predominantly as immunotherapy targeting and reversing increased T-cell proliferation and immune activation.
